GILD

Gilead Sciences is expected to report Q3 2026 earnings on October 29 with a year-over-year earnings decline but higher revenues. The company has a positive Earnings ESP of +2.24% combined with a Zacks Rank #2, suggesting it will likely beat consensus EPS estimates. Gilead has beaten consensus estimates in all four of the last quarters.

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

Gilead Sciences stock fell 1.88% to $153.57, underperforming the broader market which gained between 0.58% and 1.05%. The company is scheduled to report earnings on October 29, 2026, with forecasted EPS of $2.16 (down 12.55% year-over-year) and revenue of $7.81 billion (up 0.59%). Despite the recent decline, Gilead maintains a Zacks Rank #2 (Buy) rating with a modest 1.14% upward revision in consensus EPS estimates over the past month.

Gilead Sciences (GILD) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting an upward trend in earnings estimates over the past three months with a 39.1% increase in consensus estimates. The upgrade positions the company in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals and institutional investor buying pressure.

Gilead Sciences has outperformed broader equities this year, climbing nearly 30%, driven by strong financial results and regulatory progress. The company's Q2 revenue reached $7.8 billion (up 10% YoY), with HIV products generating $5.7 billion.

Recent FDA approvals include Bixlenvo for HIV and Hepcludex for hepatitis delta, while Trodelvy received a label expansion for first-line metastatic triple-negative breast cancer treatment. With a solid dividend yield of 2.2% and flagship products like Biktarvy, Gilead appears attractive for long-term investors despite the stock's recent gains.

Gilead Sciences (GILD) closed at $157.48, up 2.57%, outperforming the S&P 500. The HIV and hepatitis C drugmaker is expected to report EPS of $2.16 (down 12.55% YoY) with quarterly revenue of $7.81 billion (up 0.59% YoY).

The company holds a Zacks Rank #3 (Hold) with a recent upward EPS estimate revision of 1.52%. Its industry ranks in the bottom 38% of all sectors.

Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies.

Gilead Sciences (GILD) has attracted investor attention with a +4% return over the past month, outperforming the broader market's +2.1% gain. However, the company faces headwinds with expected earnings declining 12.6% year-over-year for the current quarter and a significant fiscal year loss of -$0.47 per share. The stock holds a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term, while trading at par with its peers on valuation metrics.

The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation.

The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.

Gilead Sciences (GILD) closed at $151.17, up 2.77% and outperforming the S&P 500. The HIV and hepatitis C drugmaker is expected to report a 13.36% EPS decline for the upcoming quarter, though revenue is projected to increase 0.51%. The stock holds a Zacks Rank #3 (Hold) rating, with the Medical - Biomedical and Genetics industry ranked 177th out of 250+ industries.

Gilead Sciences stock declined 1.87% to $144.74 while broader markets gained, underperforming the S&P 500's 0.73% rise. The HIV and hepatitis C drugmaker has lost 2.46% over the past month, with the Medical sector down 3.74%.

Upcoming earnings are projected at $2.15 per share (down 12.96% year-over-year) with revenue expected at $7.79 billion (up 0.3%). The stock holds a Zacks Rank #3 (Hold) rating.

Gilead Sciences (GILD), an HIV and hepatitis C drugmaker, is a trending stock with mixed fundamentals. The company maintains a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the broader market.

While Gilead has beaten consensus estimates in the last four quarters and shows modest revenue growth forecasts of 4.4% and 6.1% for the current and next fiscal years, earnings estimates remain challenged with a projected -105.9% year-over-year change for the current fiscal year. The stock is valued at par with its peers.

Gilead Sciences declined 1.21% on September 30, 2026, underperforming the S&P 500's 0.25% loss. The HIV and hepatitis C drugmaker faces headwinds with projected quarterly EPS down 12.96% year-over-year, though revenue is expected to rise slightly by 0.3%. The company holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 2.2% lower over the past month.

The article compares two healthcare sector ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on 27 pharmaceutical companies, and iShares Biotechnology ETF (IBB), which covers 243 biotech stocks. IBB has a lower expense ratio (0.44% vs 0.58%) and outperformed over the past year (37.7% vs 33.9% return), but PJP offers higher dividend yield (0.92% vs 0.16%) and lower volatility. The choice depends on investor risk tolerance and portfolio goals.

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR.

North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years.

The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV.

The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.

VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).